Since the European Court of Justice ruled in favour of non-psychotropic cannabinoids at the end of 2020, CBD has been conquering Europe, with a market value estimated at €2.2 billion by 2022, according to a recent study. And consumer enthusiasm is undiminished, with over 11% of the French population having already consumed CBD products on an occasional or regular basis. Since then, the range of products on offer has become much more diverse, both in terms of formats and packaging (oil, flowers, concentrates, edibles, puffs, e-liquids, etc.) and in terms of the molecules on offer, with CBD and its acolytes CBG, CBC and CBN, of course, but also more dubious substances such as THCV, THCP and H4CBD. Since HHC was banned by the Ministry of Health following the opinion issued by the French National Agency for the Safety of Medicines (ANSM) in June 2023, some suppliers have started to promote a substitute molecule, H4CBD. At Famous CBD, we are concerned about the direction the legal hemp market is taking. That's why we've put together a series of articles on these 'new' molecules. Our aim is to give you the keys to making informed choices. Today, we're putting H4CBD under the microscope and, as you'll see, we're a long way from the virtues of CBD.